Amgen-AZ combo cuts small cell lung cancer deaths 58% in phase 3
Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced death risk by 58% in extensive-stage small cell lung cancer patients, per phase 3 trial results. Median overall survival was 21.1 months vs. 12.7 months for Imfinzi alone. The combination also extended progression-free survival but had higher side effects. Results were presented at ESMO 2026 and published in NEJM.
How this was made
The 30-second read
Why it matters
The data could reshape treatment standards for extensive‑stage small cell lung cancer and affect both Amgen's and AstraZeneca's oncology revenue forecasts.
Market read
First‑time reporting of a major survival benefit in a hard‑to‑treat cancer, likely to move both stocks and the broader oncology sector.
What to watch
Regulatory approval timelines and reimbursement uncertainty may delay commercial impact.
Background
The DeLLphi‑305 phase 3 trial results were unveiled at the European Society for Medical Oncology meeting and published in NEJM, marking the first public disclosure of these efficacy numbers.
Ticker impact
Phase 3 trial showed Amgen's Imdelltra plus AstraZeneca's Imfinzi cut death risk by 58% in extensive‑stage small cell lung cancer.
upward pressure as market prices in the survival benefit
First disclosure of statistically significant survival improvement; investors typically reward such breakthroughs.
AstraZeneca's immunotherapy Imfinzi combined with Amgen's Imdelltra reduced mortality by 58% in a phase 3 small cell lung cancer study.
upward pressure as market incorporates expanded indication
First report of a major efficacy gain; analysts may raise forecasts for the oncology franchise.
Market effects
Strengthens the oncology/biotech sector outlook, may lift peers developing DLL3‑targeted therapies.
European biotech markets could see modest gains as the data were presented in Madrid.
Potentially influences global cancer‑treatment pipelines and investor sentiment toward immunotherapy.
Counterpoint
Higher adverse‑event rates (CRS, ICANS) could temper enthusiasm and raise safety concerns.
Key entities
- CompanyAmgen Inc.
Biopharma developer of Imdelltra.
- CompanyAstraZeneca plc
Producer of the immunotherapy Imfinzi.
